Login
Products
Login
Home
Alerts
Search
Watchlist
Products

AVI Products India Ltd

APIL
BSE
45.28
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

AVI Products India Ltd

APIL
BSE
45.28
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
15Cr
Close
Close Price
45.28
Industry
Industry
Trading
PE
Price To Earnings
PS
Price To Sales
5.48
Revenue
Revenue
3Cr
Rev Gr TTM
Revenue Growth TTM
-34.22%
PAT Gr TTM
PAT Growth TTM
-1,241.67%
Peer Comparison
How does APIL stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
APIL
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
111111112100
Growth YoY
Revenue Growth YoY%
-29.638.816.851.132.1-4.5-28.8-20.452.3-45.3-78.7-70.8
Expenses
ExpensesCr
111111112111
Operating Profit
Operating ProfitCr
0000000000-10
OPM
OPM%
16.10.916.04.21.94.75.6-7.10.6-65.5-284.2-142.4
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
0000000000-10
Tax
TaxCr
000000000000
PAT
PATCr
0000000000-10
Growth YoY
PAT Growth YoY%
-40.0-80.0133.3-50.066.7300.0-92.9-400.0-80.0-1,100.0-5,600.0-1,366.7
NPM
NPM%
7.40.911.20.79.33.81.1-2.61.2-69.0-289.5-133.3
EPS
EPS
0.20.10.40.00.30.10.0-0.10.1-1.2-1.7-1.3

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
222434234553
Growth
Revenue Growth%
-3.6-0.816.873.7-4.619.3-41.940.08.334.2-2.9-42.0
Expenses
ExpensesCr
113334233554
Operating Profit
Operating ProfitCr
10000000000-1
OPM
OPM%
28.819.7-22.75.25.34.40.06.58.25.60.4-50.5
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000000000000
Depreciation
DepreciationCr
000000000000
PBT
PBTCr
10000000000-1
Tax
TaxCr
000000000000
PAT
PATCr
00000000000-1
Growth
PAT Growth%
-33.1-28.6-248.1128.2-11.922.9-53.6103.477.524.0-78.9-2,651.2
NPM
NPM%
21.315.3-19.43.12.93.02.43.55.75.31.1-50.2
EPS
EPS
3.62.6-3.91.11.01.20.61.10.80.80.2-4.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
111111133333
Reserves
ReservesCr
010000122443
Current Liabilities
Current LiabilitiesCr
100111100111
Non Current Liabilities
Non Current LiabilitiesCr
000000000000
Total Liabilities
Total LiabilitiesCr
222222355887
Current Assets
Current AssetsCr
211122244776
Non Current Assets
Non Current AssetsCr
001111001211
Total Assets
Total AssetsCr
222222355887

Cash Flow

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
00000000-10-1
Investing Cash Flow
Investing Cash FlowCr
00000000-2-10
Financing Cash Flow
Financing Cash FlowCr
00000002021
Net Cash Flow
Net Cash FlowCr
00000002-220
Free Cash Flow
Free Cash FlowCr
00000000-1-1-1
CFO To PAT
CFO To PAT%
17.3116.19.741.6-281.9254.0-255.184.2-301.0121.0-1,436.9
CFO To EBITDA
CFO To EBITDA%
12.890.18.325.1-155.9173.0-14,081.145.4-208.6113.8-4,460.1

Ratios

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
002020111497
Price To Earnings
Price To Earnings
0.00.00.00.023.80.016.295.021.336.4131.3
Price To Sales
Price To Sales
0.00.01.10.00.70.00.43.31.21.91.5
Price To Book
Price To Book
0.00.02.00.01.70.00.62.51.01.31.0
EV To EBITDA
EV To EBITDA
-0.7-1.2-4.8-0.614.50.31,275.241.110.022.8263.6
Profitability Ratios
Profitability Ratios
GPM
GPM%
66.457.427.133.441.231.632.338.139.634.834.2
OPM
OPM%
28.819.7-22.75.25.34.40.06.58.25.60.4
NPM
NPM%
21.315.3-19.43.12.93.02.43.55.75.31.1
ROCE
ROCE%
41.426.2-32.810.28.010.15.64.76.94.71.6
ROE
ROE%
28.917.1-33.88.77.18.03.62.74.53.60.8
ROA
ROA%
18.914.6-26.35.84.15.22.12.44.33.10.7
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
AVI Products India Limited is an Indian listed entity currently undergoing a fundamental structural and strategic transformation. Historically focused on the trading and distribution of dental healthcare and food products, the company is pivoting toward the real estate sector following a **change in control and management** initiated in **February 2026**. --- ### **Corporate Transformation & Change in Control** The company is in a critical transition phase governed by the **SEBI (Substantial Acquisition of Shares and Takeovers) Regulations**. This shift marks the exit of the founding promoters and the entry of new leadership with a different sectoral focus. * **The Acquirer:** **PPMS Real Estates LLP** ("Acquirer") triggered a mandatory open offer in **April 2026** to acquire up to **26%** of the voting share capital at **₹33.00 per share**. * **Acquisition Mechanics:** The Acquirer deposited **100%** of the offer consideration (**₹2.84 crore**) into an escrow account. As of **April 2026**, the Acquirer holds an aggregate stake of **34.72%**, comprising: * **23.68% (7,83,091 shares)** from the original Vora family promoters. * **11.04% (3,65,030 shares)** from non-promoter sellers. * **Management Overhaul:** The previous promoters have ceased control. The Board is being reconstituted, notably including the appointment of **Ms. Malvika Jaggani** as an Additional Non-Executive Independent Director for a **5-year** term. * **Geographic Shift:** To align with new management, the registered office is relocating from **Vasai, Palghar** to **Khar (West), Mumbai**. --- ### **Strategic Pivot: Real Estate & Infrastructure Development** Under the leadership of **PPMS Real Estates LLP**, AVI Products has amended its Memorandum of Association to shift its primary business objective toward the real estate industry. * **Core Real Estate Objectives:** The company now aims to act as builders, developers, and contractors for: * **Residential & Commercial Premises:** Flats, shops, offices, and shopping malls. * **Specialized Infrastructure:** Software technology parks, hotels, and integrated resorts. * **Financial Scaling for Expansion:** To facilitate this capital-intensive pivot, the company has secured shareholder approval to significantly increase its financial headroom: * **Borrowing Limits:** Increased to **₹500 Crores**. * **Investment/Loan Limits:** Increased to **₹500 Crores** for providing loans, guarantees, or securities. --- ### **Legacy Business Segments: Healthcare & Food** While the company pivots to real estate, it maintains its legacy operations in the ordinary course of business. These segments provided the historical revenue base for the company. #### **1. Dental & Healthcare Division** * **E-commerce Distribution:** Operates the proprietary portal **'Dentaldeal.in'**, marketing dental consumables and machinery. * **Product Strategy:** Focuses on Indian-made endodontic files and equipment, positioned as cost-effective alternatives to expensive imports. Digital marketing is used to bypass traditional dealer margins. * **Healthcare Centers:** A **2024** initiative aimed to establish up to **300** healthcare centers in **Tier 1 and Tier 2** cities. * **Partnerships:** Includes an agreement with **SABKADENTIST** and explorations into medical tourism and OPD consultations. #### **2. Food & Beverages (IFRUIT Brand)** * **Product Range:** Designs equipment for innovative ice cream formats, including **Rolls, Soft serve, Gelatos, and Sorbets**. * **Franchise Model:** Operates a distribution model under the **IFRUIT** brand. * **QSR Expansion:** Plans exist to establish a chain of **Quick Service Restaurants (QSR)** to capture growing fast-food demand. --- ### **Financial Performance & Capital Structure** The company has maintained a **100% fully paid-up** equity share capital structure with no pledged shares. #### **Key Financial Metrics** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | - | **₹5.05 Crores** | **₹3.70 Crores** | | **Net Profit** | **₹5.37 Lakhs** | **₹25.49 Lakhs** | **₹20.56 Lakhs** | | **Dividend** | **Nil** | **Nil** | **Nil** | | **Audit Opinion** | **Unmodified** | **Unmodified** | **Unmodified** | #### **Fundraising History** * **September 2023:** Raised **₹2.61 Crore** via preferential allotment of **8,43,200** shares at **₹31** (including **₹21** premium). * **September 2024:** Increased Authorized Capital from **₹3.50 Crore** to **₹7.50 Crore**. * **Internal Controls:** **F P Vora & Co Chartered Accountant** serves as the Internal Auditor through **2026**, ensuring adequate financial control systems. --- ### **Related Party Exposures** The company maintains significant financial and operational links with entities associated with the former management. These transactions require ongoing monitoring and shareholder approval. | Entity Name | Nature of Support | Financial Limit | | :--- | :--- | :--- | | **Total Dental Care Pvt Ltd** | Loans, Guarantees, Securities | Up to **₹30 Crores** | | **Bharat Jyoti Impex** | Loans, Guarantees, Securities | Up to **₹30 Crores** | | **Healix Healthcare Pvt Ltd** | Business Requirement Support | Principal Business Activities | --- ### **Risk Profile & Investor Considerations** #### **1. Transition and Execution Risk** The shift from a trading/distribution model to a capital-heavy real estate and infrastructure model carries significant execution risk. The company must navigate the transition of its board and registered office while managing the **SEBI (SAST)** compliance requirements. #### **2. Regulatory & Listing Compliance** * **Minimum Public Shareholding (MPS):** If the acquisition by **PPMS Real Estates LLP** reduces public holding below **25%**, the company must execute a **Rights Issue, QIP, or Offer for Sale** to restore compliance. * **Open Offer Withdrawal:** Under **Regulation 23(1)**, the offer could be withdrawn if specific conditions in the **February 2026 SPA** are not met. #### **3. Market and Financial Risks** * **Currency & Competition:** The dental segment is sensitive to **exchange rate volatility** and freight costs. It faces intense pressure from low-cost suppliers and rapid technological obsolescence. * **Liquidity Risk:** The company must manage rolling forecasts to meet liabilities, especially as it scales borrowing limits to **₹500 Crores**. * **Management Dependency:** Historically, the company relied on the expertise of **Mr. Avinash Vora** and **Mr. Vikram Vora**. The loss of their technical knowledge during the management handover may impact legacy operations.